Healthcare Cloud Computing Market - Use of Blockchain in the Health Cloud

This study involved the four major activities in estimating the size of the healthcare cloud computing market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Market Size Estimation:

For the calculation of the market value, the revenue from providers was arrived at, based on the adoption rate and average expenditure on software and services in the healthcare cloud computing market. This process involved the following steps:

# Generating a list of the number of providers (hospitals, small group practices, and independent PCPs, etc.) adopting healthcare cloud computing solutions in the given year.

# Understanding the yearly average of expenditure undertaken by the various types of providers for these solutions.

# Totaling the yearly revenue to arrive at the overall market size.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=347

Expected Growth in Revenue:

The global Healthcare Cloud Computing Market is expected to reach USD 64.7 billion by 2025 from USD 28.1 billion in 2020, at a CAGR of 18.1%.

Global Growth Boosters:

The increasing adoption of big data analytics, wearable devices, and IoT in healthcare and the advantages of cloud usage, such as improved storage, flexibility, and scalability of data, technological advancements in healthcare infrastructure, and increasing cloud deployments in the healthcare industry are the key drivers of the healthcare cloud computing market growth. Rising patient population worldwide and subsequent increase in the burden on healthcare systems will further upsurge the demand for healthcare cloud computing solutions.

The healthcare cloud computing market includes Tier I and II vendors like IBM, athenahealth, Siemens Healthineers, and Allscripts among others. The companies have a large market spread across various countries in North America, Europe, Asia Pacific and Rest of the World. The global COVID-19 outbreak has positively impacted the business to a certain extent. Companies are opting for cloud computing infrastructure to achieve higher operational efficiency, leading to shorter waiting times and enhanced patient access, especially in these times of pandemic. Cloud services help to eliminate the inconvenience of remote working and allows communication, collaboration, and monitoring of work while ensuring employee safety.

COVID-19 Impact on the Healthcare Cloud Computing Market:

The COVID-19 outbreak, has upended many lives and businesses on an unprecedented scale. However, if there is one sector that has emerged stronger from this event, it would be the cloud computing industry. While many organizations are finding it difficult to run smoothly, the companies that opted for cloud computing infrastructure are functioning well.

Cloud computing assists in hassle-free data storage and backup because of its scalability, and also enables one to scale back during hectic days. Moreover, the social distancing measures have mandated patients with mild symptoms to opt for remote consultation. With many healthcare providers giving consultation over video conferencing and phone calls, in place of this pandemic, the growth of healthcare cloud computing market is likely to augment considerably over the forecast period.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=347

Geographical Growth:

The Asia Pacific healthcare cloud computing market to grow at the highest CAGR during the forecast period

While North America is expected to dominate the global healthcare cloud computing market in 2020, followed by Europe, the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high regional growth is attributed to the various initiatives undertaken in the APAC countries to implement new policies and to rework existing policies with public and private healthcare organizations to digitalize healthcare and increase operational efficiency. The technological revolution is thus expected to boost the healthcare cloud computing market growth in this region.

Key Players:

The major players operating in the healthcare cloud computing market include IBM (US), CareCloud Corporation (US), athenahealth (US), Hyland Software (US), Siemens Healthineers (Germany), eClinicalWorks (US), Koninklijke Philips NV (Netherlands), NTT DATA (Japan), Allscripts Healthcare Solutions (US), Fujifilm Holdings (Japan), GE Healthcare (US), Dell Technologies (US) and EnSoftek (US).

Pharmaceutical Drug Delivery Market worth $2,015.3 billion by 2025

This study involved four major activities to estimate the current size of the pharmaceutical drug delivery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

The global market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period. The factors supporting market growth include the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements & new product launches.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

The home care settings segment is expected to grow at the highest CAGR during the forecast period

Based on facility of use, the pharmaceutical drug delivery market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. The home care settings segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing use of various drug delivery devices such as injectables, nebulizers, and inhalers in home care settings.

In 2019, the infectious diseases segment accounted for the largest share

Based on application, the pharmaceutical drug delivery market is segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2019, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this segment can be majorly attributed to the increasing prevalence of infectious diseases and increasing company initiatives to enhance R&D related to infectious diseases. Further, spread of COVID-19 has further propelled the market for this application

North America was the largest regional market for pharmaceutical drug delivery in 2019

The global pharmaceutical drug delivery market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the market. The large share of the North American market can be attributed to factors such as growth in biologics in the pharmaceuticals market; the rising prevalence of chronic diseases increasing patient compliance to innovative drug delivery technologies; and the presence of a large number of prominent players in this region.

Global Leaders:

The global pharmaceutical drug delivery market is highly competitive owing to the presence of several large and small players. Johnson & Johnson, Inc. (US), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (US), Bayer AG (Germany), Pfizer, Inc. (US), Novartis AG (Switzerland), 3M Company (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc, (UK), Sanofi (France), and Antares Pharma, Inc. (US) are some of the leading players operating in the pharmaceutical drug delivery market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

North American Healthcare IT Market - Expected Revenue Growth Will be Worth $239.9 billion by 2025

The North America healthcare IT market size is projected to reach USD 239.9 billion by 2025 from USD 96.3 billion in 2019, at a CAGR of 16.4% during the forecast period. A majority of this growth is attributed to the growing adoption of various healthcare IT solutions by providers to meet the heightened regulatory requirements for patient care and safety, increasing need to curtail soaring healthcare costs, and growing need to improve the quality of healthcare while maintaining the operational efficiency of healthcare organizations.

Based on products and services, the healthcare providers segment accounted for the largest share of the North America healthcare IT market in 2018

Based on the products and services, the healthcare providers segment accounted for the largest share of the North American healthcare IT market in 2018. The large share of this segment is mainly attributed to the rising adoption of EHRs and other hospital information systems by healthcare providers, the inclination of the healthcare industry towards deployment of interoperable solutions, and growing regulatory requirements regarding patient information and safety. In this report, the healthcare provider solutions segment is segmented further into clinical solutions and non-clinical solutions. EHR, mHealth solutions, and PACS & VNA are some of the key clinical healthcare IT solutions covered in this report.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1190

By components, the services segment accounted for the largest share of the North America healthcare IT market in 2018

Based on components, the market is segmented into services, software, and hardware. In 2018, the services segment accounted for the largest share of the North American healthcare IT market. This is attributed to the introduction of complex software, the need for integration and interoperability of software, and the growing demand for consulting and outsourcing of various healthcare processes such as revenue cycle management, EHR management, pharmacy information management, and fraud detection.

By end-users, the healthcare providers segment accounted for the largest share of the North America healthcare IT market in 2018

Based on end-users, the North American healthcare IT market is segmented into healthcare providers and healthcare payers. The healthcare providers segment is divided further into hospitals; ambulatory care centers; home healthcare agencies, nursing homes, and assisted living facilities; diagnostic and imaging centers; and pharmacies.

The healthcare payers segment is divided further into private payers and public payers. Hospitals form the largest end-user segment of the North American healthcare IT market, owing to the huge demand for various HCIT solutions among hospitals to manage the increasing load of patient information generated in hospitals and growing need to improve the quality of healthcare while improving operational efficiencies within organizations.

Global Leaders:

Some of the prominent players operating in the North America healthcare IT market are McKesson Corporation (US), Oracle Corporation (US), GE Healthcare (US), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Athenahealth, Inc. (US), Infor, Inc. (US), Cognizant (US), Dell Technologies (US), and CVS Health (US).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1190

Veterinary PoC Diagnostics Market - Growing Demand for Pet Insurance & Increasing Pet Care Expenditure

Market Size Estimation:

The total market size for the veterinary point-of-care diagnostics market was arrived at after data triangulation from three different approaches, as mentioned below.

Approach to calculate revenue of different players in the veterinary point-of-care diagnostics market

In this report, the revenue of individual companies were gathered from public sources and databases. In certain cases, the share of veterinary point-of-care diagnostics business for kits & analyzers was ascertained after a detailed analysis of various parameters, including product portfolio, market positioning, selling price, and geographic reach & strength, among others. Individual shares or estimates were validated through expert interviews.

Approach to calculate parent markets of the veterinary point-of-care diagnostics market

In this report, the veterinary companion animal diagnostics market, veterinary radiography systems market, veterinary ultrasound imaging systems market, veterinary CT scanners market, and veterinary imaging market from MnM’s repository were referred to in order to obtain the market size of the veterinary point-of-care diagnostics market. A weighted average of numbers obtained from these reports was taken to derive the market size of the global veterinary point-of-care diagnostics market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105329994

Expected Revenue Growth:

The global veterinary point-of-care diagnostics market size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of 8.9%.

Major Growth Boosting Factors:

Factors such as increasing prevalence of zoonotic diseases among companion and livestock animals and the growing need for the rapid detection of these diseases, along with the advantages of POCT over laboratory analysis are driving the growth of this market during the forecast period. However, the high cost of veterinary imaging instruments is restraining the growth of this market to some extent.

By technology, the clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostic kits and analyzers market in 2018

Based on technology, the market is segmented into immunodiagnostics, clinical biochemistry, molecular diagnostics, hematology, urinalysis, and other technologies. In 2018, the clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostic kits and analyzers industry. The higher preference for various advanced clinical diagnostic products by veterinarians and pet owners are contributing to the large share of this segment.

Geographical Growth Survey:

North America will continue to dominate the market during the forecast period

The market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the veterinary point-of-care diagnostics market in 2018. The large share of North America in the global market can be attributed to the increasing adoption of companion animals, growing veterinary healthcare expenditure, and rising demand for animal-derived food products.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=105329994

Global Leaders:

Prominent players in the veterinary point-of-care diagnostics market include Zoetis, Inc. (US), IDEXX Laboratories, Inc. (US), Heska Corporation (US), Virbac (France), Thermo Fisher Scientific, Inc. (US), Eurolyser Diagnostica GmbH (Austria), Woodley Equipment Company (UK), Randox Laboratories LTD. (UK), AniPOC, Ltd. (UK), Carestream Health, Inc. (a part of ONEX Corporation) (Canada), NeuroLogica Corporation (a part of Samsung Electronics Co. Ltd.) (South Korea), and FUJIFILM SonoSite (a part of FUJIFILM Holdings Corporation) (Japan).

Active Pharmaceutical Ingredient Market - Emerging Trends to Boost the Global Industry Revenue

Overview of This Study:

This study involved four major activities in estimating the current size of the Active Pharmaceutical Ingredient Manufacturing Market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Research Methodologies Followed for This Research:

Secondary Research:

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the active pharmaceutical ingredients market. The secondary sources used for this study include Active Pharmaceutical Ingredients Committee (APIC), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), International Pharmaceutical, Congress Advisory Association (IPCAA), European Generic and Biosimilar Medicines Association (EGBMA) and World Health Organization (WHO). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

Primary Research:

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Recent Developments in the Global Active Pharmaceutical Ingredient Market:

# In 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.

# In 2020, Novartis (Switzerland) acquired Aspen’s Japanese operations to strengthen its position in the global generics and off-patent medicines market. Novartis also entered into a manufacturing and supply agreement with Aspen.

# In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.

Expected Revenue Growth:

The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period. The rising drug R&D, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. On the other hand, unfavorable drug price control policies across various countries and high manufacturing costs are expected to restrain the growth of this market are the major factors driving the growth of this market.

North America was the largest regional market for active pharmaceutical ingredients market in 2019

The global active pharmaceutical ingredient market is segmented into North America, Europe, Asia, Latin America, and Rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia. The large share of North America in the global market is attributed to the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=263

However, the market in the Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to the low manufacturing costs, growth in the increase in disposable income, the high prevalence of lifestyle- and age-related diseases, and government efforts to reform healthcare industry.

Key Players:

The global Active Pharmaceutical Ingredient Manufacturing Market is highly consolidated. Prominent players in the active pharmaceutical ingredients market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK). 

Top 10 Bioprocess Technology Market - Key Players Are Adopting Different Growth Strategies

Top 10 bioprocess technology market is dominated by GE Healthcare (U.S.), Merck Millipore (Germany), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), and Danaher Corporation (U.S.).

GE Healthcare accounted for the largest share of the global top 10 bioprocess technology market in 2015. The company is engaged in drug discovery, patient monitoring systems, medical imaging solutions, performance improvement solutions, information technologies, medical diagnostics, patient monitoring systems, and biopharmaceutical manufacturing technologies. Healthcare Systems, Life Sciences, and Healthcare IT are the major business segments of the company.

The company primarily focusing on inorganic growth strategies to maintain its footprint in the market. In accordance with this, in November 2016, GE healthcare has expanded its single-use technology manufacturing facility of their life science business segment, to the biotechnology industry. In August 2016, GE healthcare and Sealed Air (U.S.), entered into extended agreement to deliver new film suitable for use in GE’s full single-use bioprocess portfolio.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30722776

Merck Millipore held the second position in the top 10 bioprocess technology market. The company has a strong geographic presence across the globe spanning from North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company operates in four business segments, namely, Biosciences, Lab Solutions, Process Solutions, and Sigma-Aldrich. These segments offer a wide range of products and technologies such as Chromatography, Sterile Filtration, and Ultrafiltration (UF).

In order to maintain its position in the market, the company pursues organic as well as inorganic growth strategies. In 2016, the company launched two products in the bioprocess technology market, namely, Mobius 1000L single-use bioreactor and Mobius Power MIX 2000, a single-use mixing system. In December 2016, Merck extended their distribution agreement with Roche (Switzerland) under this extended agreement Merck has incorporated new products to Roche’s distribution product portfolio. This agreement enhanced Merck’s existing distribution relationship with Roche.

Other prominent players in the top 10 bioprocess technology market include Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Lonza Group AG (Switzerland), Sartorius Stedim Biotech S.A (France), Corning, Inc.(U.S.), Bio-Rad Laboratories (U.S.), and Charles River Laboratories (U.S.).

Different Growth Strategies Adopted by Key Players:

An analysis of the market developments between 2014 and 2016 revealed that product launches and agreements & collaborations was the most important growth strategy adopted by market leaders.

The other important growth strategy adopted by players in this market was mergers & acquisitions, expansions, and product approvals. This strategy was adopted by market players to enhance their product portfolio and geographic presence. Danaher Corporation (U.S.), Lonza Group AG (Switzerland), Merck Millipore (Germany), and Thermo Fisher Scientific, Inc. (U.S.) are some of the companies that adopted this strategy.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=30722776

ePrescribing Market - Global Players & Different Growth Strategies Adopted by Them

Expected Global Revenue Growth:

The global ePrescribing market size is projected to reach USD 3.3 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 23.3%.

Major Growth Boosting Factors:

Factors such as the increasing adoption of EHR solutions, government initiatives and incentive programs, rising focus on reducing the abuse of controlled substances, increasing focus on reducing medical errors, and the need to curtail the escalating healthcare costs are driving the growth of the e-prescribing market. Additionally, the onset of the COVID-19 pandemic has accelerated the use of telemedicine modules and telehealth consultations. This is further driving the adoption of e-prescribing solutions.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=910

Key Players:

Some of the other prominent players operating in the ePresciribing market are Prominent players in the global e-prescribing market are NextGen Healthcare (US), athenahealth, Inc. (US), RelayHealth, LLC (US), Henry Schein, Inc. (US), GE Healthcare (US), Computer Programs and Systems Inc. (US), DrFirst, Inc. (US), Surescripts-RxHub, LLC (US), and Medical Information Technology, Inc. (US). Major players in this market pursued the strategies of agreements, collaborations, and partnerships as their growth strategies. In 2019, Cerner Corporation (US),  EPIC Systems Corporation (US), and Allscripts (US) dominated the global ePrescribing  industry.

Cerner Corpration (US) is a leading provider of e-prescribing solutions to hospitals, pharmacies, and officebased physicians. Cerner mainly focuses on inorganic growth strategies such as collaborations, agreements, and partnerships. In line with this strategy, Cerner collaborated with Mayo Clinic and OxfordClinic in London to help them leverage their Millennium EHR platform in the UK.

It also signed agreements with other countries in Europe, such as Sweden, to help them leverage its healthcare IT solutions. The company also focuses on expanding its business globally in order to strengthen its position in the eprescribing market, particularly in the high-growth Asia Pacific and Latin American regions. Currently, Europe and North America account for about 90% of the company’s e-prescribing business.

Epic Systems Corporation (US) accounted for the second-largest share of ePrescribing market in 2019. The company specializes in interoperable solutions and mainly focuses on the needs of mediumsized and large hospitals and integrated healthcare organizations. The company has adopted various inorganic strategies such as collaborations and partnerships, which has helped it to enhance its product offerings. Additionally, the company’s integrated telehealth portals have helped hospitals, especially during the COVID-19 pandemic, where telehealth consultations have risen to close to 50% of the total visits. As telemedicine is closely followed with medical prescriptions via e-prescribing solutions, the company is expected to witness increased use of the functionality during the pandemic.

Allscripts Healthcare Solutions, Inc.(US) provides innovative clinical software and services that deliver significant benefits to patients and healthcare professionals. The company focuses on R&D activities to enhance its service offerings. In 2019, the company invested USD 254.5 million—about 14% of its total revenue—on R&D.

In November 2018, Allscripts announced Veradigm as the new brand for its life science division and now provides e-prescription modules to healthcare providers under the Veradigm brand. Another factor contributing to the major share of the company is its agreement with CoverMyMeds for the Allscripts electronic prior authorization (ePA) software to enable prescription providers to quickly authorize prescriptions electronically. CoverMyMeds is the largest ePA platform in the US and includes a network of 60,000 pharmacies and 700,000 providers in the country.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=910

APAC will grow at the fastest rate during the forecast period.

The ePresciribng market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Currently, a number of healthcare organizations in the Asia Pacific region are actively moving towards digitization with a focus on streamlining their entire workflow and ensuring patient safety. Japan, Australia, Taiwan, South Korea, India, and China are the major countries in this region that are actively adopting e-prescribing solutions.

In addition, government initiatives for the adoption of EMR solutions, the large volume of COVID-19 patients, the growth of the geriatric population, the rising prevalence of chronic diseases, increasing healthcare expenditure, and the growing purchasing power of consumers are also impacting the growth of this region in the coming years. 

Pharmaceutical Drug Delivery Market worth $2,015.3 billion by 2025

Overview of This Research Study:

This study involved four major activities to estimate the current size of the pharmaceutical drug delivery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Expected Revenue Surge:

The pharmaceutical drug delivery technology market is projected to reach USD 2,015.3 billion by 2025 from USD 1,430.5 billion in 2020, at a CAGR of 7.1% during the forecast period.

Major Growth Influencing Factors:

Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for pharmaceutical drugs largely in infectious application.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

The home care settings segment is expected to grow at the highest CAGR during the forecast period

Based on facility of use, the pharmaceutical drug delivery market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. The home care settings segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing use of various drug delivery devices such as injectables, nebulizers, and inhalers in home care settings.

In 2019, the infectious diseases segment accounted for the largest share

Based on application, the pharmaceutical drug delivery market is segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2019, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this segment can be majorly attributed to the increasing prevalence of infectious diseases and increasing company initiatives to enhance R&D related to infectious diseases. Further, spread of COVID-19 has further propelled the market for this application

Geographical Growth Scenario:|

North America was the largest regional market for pharmaceutical drug delivery in 2019

The global pharmaceutical drug delivery market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the market. The large share of the North American market can be attributed to factors such as growth in biologics in the pharmaceuticals market; the rising prevalence of chronic diseases increasing patient compliance to innovative drug delivery technologies; and the presence of a large number of prominent players in this region.

Key Players:

The global pharmaceutical drug delivery market is highly competitive owing to the presence of several large and small players. Johnson & Johnson, Inc. (US), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (US), Bayer AG (Germany), Pfizer, Inc. (US), Novartis AG (Switzerland), 3M Company (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc, (UK), Sanofi (France), and Antares Pharma, Inc. (US) are some of the leading players operating in the pharmaceutical drug delivery market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Healthcare Claims Management Market worth 13.93 billion USD by 2023

The key factors driving the growth of this market are increasing patient volumes, expanding health insurance market, growing importance of denials management, and declining reimbursement rates.

Expected Revenue Growth:

The healthcare claims management market is expected to reach USD 13.93 billion by 2023 from an estimated USD 10.77 billion in 2018, at a CAGR of 5.3%.

By type, integrated solutions are expected to account for the largest share of the market in 2018

On the basis of type, the healthcare claims management market is broadly segmented into integrated solutions and standalone solutions. In 2018, the integrated solutions segment is expected to account for the largest share of this market. The high growth in this segment can be attributed to increasing demand for integrated solutions, which play an integral role in improving process efficiency and reducing costs.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36752923

By end user, the healthcare payers segment is expected to command the largest share of the market in 2018

On the basis of end user, the market has been segmented into healthcare payers, healthcare providers, and other end users. The payers segment is expected to command the largest share of the market in 2018. The large share of this segment can be attributed to the mandate for insurance companies to meet the regulatory requirements and reduce unnecessary penalties and punishments.

North America to dominate the market in 2018

North America is expected to account for the largest share of the healthcare claims management market in 2018, followed by Europe. The large share of North America can be attributed to the high and growing HCIT investments in the region and the presence of regulatory mandates favoring the implementation of healthcare claims management solutions. Also, several major global players are based in the US, owing to which the US has become a center for innovation in the healthcare claims management solutions market.

Key Players:

Cerner Corporation (US), McKesson Corporation (US), athenahealth (US), eClinicalWorks (US), Optum, Inc, (US), Conifer Health Solutions (US), and nThrive (US) are the key players in the healthcare claims management solutions market. Other players involved in this market are DST Systems (US), Cognizant Technology Solutions (US), Allscripts Healthcare Solutions, Inc. (US), Context 4 Healthcare (US), Health Solutions Plus (US), GE Healthcare (US), RAM Technologies (US), Quest Diagnostics (US), The SSI Group (US), PLEXIS Healthcare Systems (US), and GeBBS Healthcare Solutions (US).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=36752923

Nerve Monitoring System Market - Emerging Trends & Global Future Forecasts

The Global Nerve Monitoring System Market is projected to reach USD 1.45 Billion by 2022 from USD 1.14 Billion in 2017, at a CAGR of 4.9% during the forecast period.

Factors such as increased target patient population, clinical benefits associated with nerve monitoring procedures, and the rising use of nerve monitoring in trauma cases are expected to drive the demand for nerve monitoring products during the study period.

Based on the technology, the electromyography segment is expected to register highest growth rate during the forecast period

Based on technology, the nerve monitoring system market is divided into electroencephalography, electromyography, electrocorticography and evoked potential. Among these segments, electromyography is expected to grow at the highest CAGR during the forecast period. Growing availability of reimbursements for EMG-assisted surgical procedures in developed countries, significant use of EMG nerve monitoring for intraoperative applications, and technological advancements in the field are expected to drive the growth of the electromyography segment in the next five years.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155669000

Based on application, neurosurgery is estimated to be the largest segment of the market in 2017.

The nerve monitoring system market is segmented by application into cardiovascular, neurosurgery, spine surgery, ENT surgery, and other applications. The neurosurgery segment is expected to have the largest share in the nerve monitoring system market in 2017, owing to increasing number of patients suffering from neurological disorders.

Based on end users, the hospitals and surgical centers segment is expected to register fastest growth rate in the forecast period

The nerve monitoring system market is segmented into hospitals and surgical centers and ambulatory surgical centers segment. The hospitals and surgical centers is projected to be the fastest-growing end-user segment due to increasing number of complex surgical procedures, and rising number of diagnostic and surgical procedures carried out at hospitals.

North America accounted for the largest share of the nerve monitoring system market

Geographically, the nerve monitoring system market is segmented into North America, Europe, Asia, and the Rest of the World. North America is estimated to account for the largest share of the market in 2017, which is driven by the presence of a large patient population accompanied by a well established medical reimbursement policy.

Global Key Players:

The major players of the nerve monitoring system market are Medtronic (Ireland), NuVasive (US), Nihon Kohden (Japan), Bovie Medical (US), and Natus Medical (US), Checkpoint Surgical (US), Magstim (UK), Inomed (Germany), Erbe Elektromedizin (Germany), Dr. Langer Medical (Germany), EMS Handels (Austria), Neurovision Medical (US), and Halyard Health (Georgia).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=155669000

Apheresis Market worth $2.7 billion by 2025

The global apheresis market is projected to reach USD 2.7 billion by 2025 from USD 1.7 billion in 2019, at a CAGR of 8.1% during the forecast period. The rising prevalence of chronic diseases and the growing number of trauma & injury cases, the rising demand for blood components and growing concerns regarding blood safety, and the favorable reimbursement for apheresis procedures are the major factors driving the growth of this market.

Overview of This Study:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Market Size Estimation:

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product, technology, application, procedure, end user, and region).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950

The centrifugation technology segment is expected to grow at the highest CAGR during the forecast period

Based on technology, the apheresis market is segmented into centrifugation technology and membrane separation technology. The centrifugation segment is expected to grow at the highest CAGR during the forecast period. This high growth can be attributed to the advantages offered by centrifugation over membrane separation, such as its high efficiency and its ability to separate all types of blood components

The photopheresis segment is expected to grow at the highest CAGR during the forecast period

Based on application, the apheresis market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, photopheresis, and other applications. The photopheresis is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing prevalence of blood disorders and the rising demand for photopheresis in organ transplant rejection treatment.

The hospitals and transfusion centers segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the apheresis market has been segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. The hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing adoption of therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis, and rising awareness of apheresis as a therapy.

North America accounted for the largest market share in 2018

North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.

The prominent players in this market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan), among other key players.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950

Key Growth Strategy Adopted by Players Operating in the Global Process Analytical Technology Market

Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Danaher Corporation (U.S.) are the leading players in the global process analytical technology market.

The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), Shimadzu Corporation (Japan), ABB Ltd. (U.S.), Carl Zeiss AG (Germany), Emerson Electric Co. (U.S.), and Mettler-Toledo International Inc. (U.S.).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=59564006

Thermo Fisher Scientific Inc. dominated the global PAT market in 2016. The company offers analytical technologies through its analytical instruments business segments, which cater to the markets in developed as well as developing countries. The company mainly focuses on product launches as its key growth strategy. The company launched many products between January 2016 and July 2016, including the Vanquish Flex Binary UHPLC system, Q Exactive BioPharma, Exactive GC Orbitrap GC-MS, Dionex Chromeleon 7.2 Chromatography Data System, and MAbPac RP column. The company also enters into collaborations, agreements, and partnerships as well as adopts expansions as a growth strategy to maintain its market presence. Thermo Fisher has a significant global footprint in almost all the regions of the world owing to its strong sales and distribution network.

Agilent Technologies, Inc. held the second position in the global PAT market in 2016. Agilent Technologies operates under three business segments, namely, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company focuses on organic growth strategies such as product launches and expansions in various territories to keep up with its competitors. Agilent offers a broad portfolio of PAT solutions and has a vast geographic presence with distribution channels across the Americas, Europe, Asia-Pacific, and the Middle East.

Danaher Corporation held the third position in the global PAT market. The company offers its process analytical technology solutions through its subsidiary, AB Sciex LLC, (U.S.). It focuses on strategies such as partnerships and collaborations to enhance its technical strengths as well as secure its market position. The company also focuses on product launches to improve its portfolio. The company has a global presence in developed regions such as North America and Europe as well as developing regions such as Asia-Pacific and Latin America.

Companies in the process analytical technology market are majorly focusing on product launches for strengthening their market share; this strategy accounted for 63.5% of the total number of strategic developments undertaken by key players in this market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=59564006

Colorcon Inc. (US), Sensient Technologies Corporation (US), BASF SE (Germany) are the leading players in the Tablet Coatings Market

The tablet coatings market is projected to reach USD 969 million by 2025 from USD 739 million in 2020, at a CAGR of 5.6% during the forecast period. Growth in this market is majorly driven by the growing pharmaceutical industry coupled with the increasing R&D activities taking place in this field. Also, the growing generics market, rapidly growing biopharmaceuticals sector, growing nutraceutical industry, and the rising adoption of orphan drugs are supporting the growth of the market.

The shifting focus of pharmaceutical manufacturing to emerging markets along with the increasing outsourcing of operations to these countries and the growing biologics and biosimilars industry present significant opportunities for market growth. The rising focus on sports nutrition and the technological advancements taking place in niche market areas also offers significant growth opportunities for players operating in this space. On the other hand, the increasing regulatory stringency regarding the approval of drugs and excipients along with the cost and time-intensive drug development process; the high cost associated with the microencapsulation process and the unfavorable drug price control policies are expected to restrain the growth of this market during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150774403

The global tablet coatings market is consolidated at the top, with a large number of leading market players based in developed countries. The prominent players in this market are Colorcon Inc. (US), Sensient Technologies Corporation (US), BASF SE (Germany), Evonik Industries AG (Germany), Ashland Global Holdings Inc. (US), DuPont De Numeours Inc. (US), Kerry Group plc (Ireland), Roquette Freres (France), Eastman Chemical Company (US), Air Liquide S.A. (France), Merck KGaA (Germany), Corel Pharma Chem (India), Biogrund GmbH (Germany), Ideal Cures Pvt. Ltd. (India), Wincoat Colours & Coatings Pvt. Ltd. (India), Spectrum Chemical Mfg. Corp. (US), Coating Place, Inc. (US), Lubrizol Corporation (US), Aquadry Pharma Pvt. Ltd. (India), and Aries Exim Pvt. Ltd. (India).

However, in the last few years, a number of smaller players have emerged from niche markets and are competing with global players based on price and technological innovation. Due to the intense competition in the market, major market players are increasingly focusing on expanding their geographic presence into high-growth emerging markets and strengthening their competitiveness in the market by acquiring smaller players with desired technological capabilities or geographic presence.

Colorcon held the leading position in the tablet coatings market in 2019. The company a wide range of immediate-release, enteric-release and sustained-release tablet coatings, along with controlled-release excipients. Colorcon is also engaged in offering a wide range of services for pharmaceutical and nutraceutical formulation development. These services range from dissolution design and patient adherence to productivity, stability, and product authentication services.

The company’s Colorcon Academy offers a series of professional programs developed to increase your technical knowledge and regulatory understanding in the areas of film coating, core formulation, excipient selection and controlled release of solid oral dosage forms. The company has a strong geographic presence established through its manufacturing and distribution facilities, across the globe. Furthermore, the company significantly invests in R&D activities to add innovative technologies and products to its portfolio. The company intends to strengthen its presence in the market by delivering superior solutions and choices to customers. The firm strongly believes that investments in R&D offer great potential for short and long-term growth.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150774403

Sensient Technologies Corporation held the second position in the global market. The company has a diversified product portfolio, which comprises of a wide range of immediate release and modified release tablet coating excipients. Sensient’s leading position in the market is attributed to its research and development activities, strong manufacturing capabilities, and wide distribution footprint across the world, which enables it to serve customers in more than 150 countries.

The company’s growth strategy for the pharmaceutical excipients business mainly concentrates on expanding its product portfolio and meet rising consumer demand. The company incessantly focuses on the development of the specialty chemicals business by investing in new product discovery. In addition to this, the company’s strategic priority is to leverage its position in the market by focusing on product launches through customer-focused innovation, which enables it to target a larger customer base and diversify its revenue streams.

Apheresis Market - Emerging Economies With Increasing Investments From Government Bodies and Leading Players

Research Methodologies Followed for This Study:

Secondary Research:

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research:

In the primary research process, industry experts from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Industry experts from the supply side include CEOs, vice presidents, marketing and sales directors, product managers, business development managers, technology and innovation directors of companies providing apheresis, key opinion leaders, and suppliers and distributors. The industry experts from the demand side include hospitals, blood collection centers, transfusion clinics, and healthcare payers.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950

End Users:

The hospitals and transfusion centers segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the apheresis market has been segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. The hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing adoption of therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis, and rising awareness of apheresis as a therapy.

Geographical Growth:

North America accounted for the largest market share in 2018

North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.

Global Leaders:

Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US) are the leading players in the apheresis market. The global apheresis market size is projected to reach USD 2.7 billion by 2025 from USD 1.7 billion in 2019, at a CAGR of 8.1% during the forecast period.

The key players of this market focus on increasing their market presence with the adoption of both organic and inorganic growth strategies. These include product launches, agreements, partnerships, collaborations, and acquisitions.

Terumo BCT, Inc. (US) was the leading player in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950

Fresenius SE & Co. KGaA (Germany) Fresenius is a global player in the apheresis market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. The company offers apheresis systems and related disposables for both donor & therapeutic apheresis through its Fresenius Kabi and Fresenius Medical Care business segments. The company strengthens its business operations by expanding its presence in emerging markets. For instance, in 2016, Fresenius introduced the AmiCORE apheresis device in Malaysia, Thailand, and Vietnam. It has a strong product portfolio, and its CE-approved products have helped it in further enhancing its presence in the apheresis market.

Haemonetics Corporation (US) Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to increase its share in the apheresis market. For instance, in 2015, the company expanded its manufacturing unit in Penang (Malaysia).

GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands) are Leading Players in the Surgical Imaging Market

The global surgical imaging market is projected to reach USD 2.4 billion by 2025 from an estimated USD 1.8 billion in 2020, at a CAGR of 6.3% during the forecast period.

The major factors driving the growth of this market include the advantages of FPDs over image intensifiers, technological advancements, reimbursement cuts for analog radiography systems, and the increasing demand for minimally invasive procedures. However, the high cost of systems is estimated to restrain the growth of this market during the forecast period.

GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany) are considered to be the leading players in the surgical imaging market.

GE HEALTHCARE (US)

GE Healthcare held the leading position in the global surgical imaging market in 2019. Its leading position in this market is attributed to the highest number of installed systems—with around 35,000 C-arms installed globally—and its wide and diverse mobile C-arm offerings. The strong, wide, and diversified portfolio of mobile C-arms is an asset to the company. Some of the biggest advantages that GE Healthcare has over its competitors are its diverse product portfolio and strong customer base (to which GE can upsell products and offer bundled services).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210534462

SIEMENS HEALTHINEERS (GERMANY)

Siemens Healthineers held the second-leading position in the market in 2019. The firm maintains its position in the market by offering eight mobile C-arms. Cios Alpha is the company’s flagship mobile C-arm that delivers excellent image quality at low dosages. The company also focuses on expanding its presence in emerging markets (such as India). For this, the company has lowered its production costs and is delivering price-competitive products in emerging markets. Siemens Healthineers has a powerful brand image, strong product portfolio, and vast geographical presence. All these factors enable the company to retain its position as a prominent player in the surgical imaging market.

KONINKLIJKE PHILIPS (NETHERLANDS)

Philips is another leading player in the surgical imaging market. The company has a strong product portfolio comprising a variety of mobile C-arm platforms that it offers under its Image-guided Therapies (IGT) segment. The IGT segment of Philips has shown strong growth in the past couple of years due to aggressive expansion in emerging markets, strong product portfolio, and strong focus on innovation. The revenues increased by 10.5% between 2017 and 2019. A strong product portfolio and focus on innovation, coupled with aggressive expansion in Asia, is enabling the company to be a prominent player in the surgical imaging market.

ZIEHM IMAGING (GERMANY)

Ziehm Imaging occupies the fourth position in the surgical imaging market. The company has over 40 years of experience in this market. Ziehm is recognized as a technological leader in the mobile C-arms segment. The company invests around 15% of its revenue in R&D. Also, a major part of its product portfolio is younger than 3 years. Ziehm Imaging was the first company to launch the flat-panel technology in the market and was the first company to launch a mobile C-arm with the motorization of all 4 axes.

Ziehm Imaging has a very strong presence in the European market and is the market leader in Germany. It has around 14,000 C-arms installed in around 70 countries globally. The company is also focusing on increasing its presence in the Asian market. It recently established Ziehm Imaging Japan Co. Ltd. to further expand its presence in Japan. Various expansions, agreements, and collaborations have enabled the company to maintain its position in the global surgical imaging market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=210534462

Fertility Test Market worth $680 Million by 2025

The fertility test market is projected to reach USD 680 Million by 2025 from USD 472 Million in 2020, at a CAGR of 7.5 %  the forecast period. Growth in this market is primarily driven by by the increasing first-time pregnancy age in women, declining fertility rate among men and women, growing number of women suffering from disorders such as PCOS, emergence of advanced ovulation monitors, and the increased awareness of fertility testing in both developed as well as developing countries.

Based on Purchase mode, OTC segment to register significant growth during the forecast period.

Based on the mode of purchase, the fertility test market is segmented into direct/prescription, OTC, and online products. In 2020 the OTC segment had the major market share and exhibited high growth. The high growth of this segment is attributed to the inclination of patients towards self-monitoring of healthcare conditions, increasing initiatives by market players to spread awareness on fertility, and the rising preference for confidentiality and accessibility of test results.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139945432

Based on Application, the female fertility testing segment is expected to account for the largest share of the fertility test market in 2020

Based on the application, the fertility test  market is segmented into female fertility testing and male fertility testing. In 2020, the female fertility testing segment accounted for a larger market share, primarily due to the decreasing female fertility rates, availability of a wide range of fertility testing options for females, increase in gynecological issues in women (such as PCOD/PCOS), and the high cost of IVF procedures.

The ovulation prediction kits segment is expected to account for the largest share during the forecast period

Based on products, the fertility test market is segmented into ovulation prediction kits, fertility monitors & male fertility testing products.  Large share is attributed to ovulation prediction kits segment due to the increasing use of ovulation prediction kits, easy over-the-counter availability and low cost, and higher accuracy than natural fertility testing techniques, such as calendar methods and cervical mucus monitoring.

The home care settings segment is expected to register the highest CAGR during the forecast period

Based on end-users, the fertility test market has been segmented based on end-user category—home care settings, hospitals and fertility clinics, and other end users. The large share and high growth of this segment can be attributed to the inclination of patients toward self-monitoring of healthcare conditions, easy access to fertility and ovulation monitors on e-commerce websites, availability of user-friendly and easy-to-handle devices, and the growing preference for the confidentiality of test results.

North America dominated the global fertility test market in 2020

North America, comprising the US and Canada, accounted for the largest share of the fertility test market in 2020. The large share of this region can primarily be attributed to factors such as high prevalence of infertility, increasing awareness about fertility testing among women, the rising age of first-time pregnancies in women, and the easy availability of ovulation and fertility monitors through e-commerce websites.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139945432

Global Key Players:

Swiss Precision Diagnostics (Switzerland), Church & Dwight (US), Prestige Brands Holdings (US), bioZhena (US), Fairhaven Health (US), Fertility Focus (UK), Geratherm Medical (Germany), Hilin Life Products (US), UEBE Medical (Germany), AdvaCare Pharma (US), AVA (Switzerland), Babystart (UK), Valley Electronics (Germany), Sensiia (UK), and Mira Care (US), among others are some of the major players operating in the global fertility test market.

Nerve Monitoring System Market worth 1.45 Billion USD by 2022

Expected Growth in Revenue in Near Future:

The Global Nerve Monitoring System Market is projected to reach USD 1.45 Billion by 2022 from USD 1.14 Billion in 2017, at a CAGR of 4.9% during the forecast period.

Major Growth Boosting Factors:

Factors such as increased target patient population, clinical benefits associated with nerve monitoring procedures, and the rising use of nerve monitoring in trauma cases are expected to drive the demand for nerve monitoring products during the study period.

Global Industry Segmentation:

Based on the technology, the electromyography segment is expected to register highest growth rate during the forecast period

Based on technology, the nerve monitoring system market is divided into electroencephalography, electromyography, electrocorticography and evoked potential. Among these segments, electromyography is expected to grow at the highest CAGR during the forecast period. Growing availability of reimbursements for EMG-assisted surgical procedures in developed countries, significant use of EMG nerve monitoring for intraoperative applications, and technological advancements in the field are expected to drive the growth of the electromyography segment in the next five years.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155669000

Based on application, neurosurgery is estimated to be the largest segment of the market in 2017.

The nerve monitoring system market is segmented by application into cardiovascular, neurosurgery, spine surgery, ENT surgery, and other applications. The neurosurgery segment is expected to have the largest share in the nerve monitoring system market in 2017, owing to increasing number of patients suffering from neurological disorders.

End Users:

Based on end users, the hospitals and surgical centers segment is expected to register fastest growth rate in the forecast period

The nerve monitoring system market is segmented into hospitals and surgical centers and ambulatory surgical centers segment. The hospitals and surgical centers is projected to be the fastest-growing end-user segment due to increasing number of complex surgical procedures, and rising number of diagnostic and surgical procedures carried out at hospitals.

Geographical Growth:

North America accounted for the largest share of the nerve monitoring system market

Geographically, the nerve monitoring system market is segmented into North America, Europe, Asia, and the Rest of the World. North America is estimated to account for the largest share of the market in 2017, which is driven by the presence of a large patient population accompanied by a well established medical reimbursement policy.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=155669000

Key Players:

The major players of the nerve monitoring system market are Medtronic (Ireland), NuVasive (US), Nihon Kohden (Japan), Bovie Medical (US), and Natus Medical (US), Checkpoint Surgical (US), Magstim (UK), Inomed (Germany), Erbe Elektromedizin (Germany), Dr. Langer Medical (Germany), EMS Handels (Austria), Neurovision Medical (US), and Halyard Health (Georgia).

Medtronic (Ireland) and Johnson & Johnson (US) are the Major Players in the Laparoscopic Repair Surgery Market

The global laparoscopic and open hernia mesh repair surgery market is projected to reach USD 3.53 Billion by 2022 from USD 3.18 Billion in 2017, at a CAGR of 2.1%. Market growth is propelled by the rising adoption of mesh in hernia repair surgeries as it is associated with a lesser risk of hernia reoccurrence, growth in the geriatric population, and ongoing advancements in this field.

The major players in the hernia mesh repair surgery market profiled in this report are Medtronic (Ireland), Johnson & Johnson (US), B. Braun (Germany), C. R. Bard (US), and W.L. Gore (US).

Medtronic (Ireland): Medtronic is a multinational medical technology company that manufactures and markets products for alleviating pain and restoring health. The company’s products are used by hospitals, clinics, third-party healthcare providers, distributors, and other institutions (including governmental healthcare programs and group purchasing organizations).

The company has a strong presence in the US market and is expanding its reach in emerging markets. For instance, in 2016, the company opened its regional headquarters in Singapore to improve its market presence in the Asia Pacific market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=260433127

Medtronic offers hernia repair products through its subsidiary Covidien. The acquisition of Covidien in January 2015 supported Medtronic in accelerating its therapy innovation, globalization, and economic value.

Covidien offers synthetic monofilament mesh, composite mesh, as well as biologic mesh. The company also offers tack applicators for mesh fixation. Medtronic was the first company to launch mesh fixation tack under the brand name – ProTack.

Johnson & Johnson (US): Johnson & Johnson offers hernia repair products through its subsidiary Ethicon. The hernia repair and fixation segment offers absorbable strap fixation devices; open absorbable strap fixation devices; polypropylene hernia systems and plugs; hernia mesh, including absorbable lightweight mesh, soft polypropylene mesh, polypropylene mesh, and woven mesh; tissue separating mesh, including flexible composite mesh, surgical mesh, ventral patches, and open flexible composite mesh devices; and biologic mesh, including tissue matrix and acellular hydrated dermis.

The presence of the company in diverse healthcare segments and strong focus on R&D and product launches are the major strengths of Johnson & Johnson. The company has a strong presence in the global medical devices market, and is the sixth largest biotech and consumer healthcare company worldwide.

Like J&J, Ethicon also has a diverse product portfolio, and more than 600 general surgical products of the company are listed in the US FDA. Most of these products have patent exclusivity in the US beyond 2020, which will help the company gain market exclusivity and ensure sustained revenue. Ethicon harnesses J&J’s worldwide infrastructure to sell its products. Ethicon also benefits through synergies with its parent company in R&D, technological knowhow, business strategies, and project implementation experience.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=260433127

Global Key Players:

The US accounted for the largest share of the hernia mesh repair surgery market in 2017. The large share of the US is attributed to the large patient population, increasing adoption of technologically advanced products, and presence of a well-established medical reimbursement policy in the country.

Animal Parasiticides Market - Major Sure in Revenue is Expected by 2025

Overview of This Study:

This market is projected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% during the forecast period. The increased pet population and increasing rising prevalence of zoonotic diseases are driving the growth of the animal parasiticides market. The base year considered for the study is 2019, while the forecast period is 2020 to 2025.

Global Industry Segmentation:

By type, the ectoparasiticides segment accounted for the largest share of the market in 2019

On the basis of type, ectoparasiticides segment accounted for the largest share of the animal parasiticides market. This can be attributed to factors such as the growing incidences of zoonotic diseases due to external parasites and increased population of companion animals.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258895412

By animal type, companion animals held the highest growth of the animal parasiticides market in 2019

On the basis of animal type, companion animals accounted for the highest growth in this market. This is attributed to the increasing number of companion animals and the rising prevalence of zoonotic diseases in dogs worldwide.

The animal farms segment is expected to witness the highest growth rate in the animal parasiticides market, by end user, during the forecast period

Based on end user, the animal farms segment is expected to register the highest CAGR during the forecast period. The increasing incidence of parasitic diseases and rising demand for animal-derived food products are the major factors supporting the growth of this segment.

North America dominated the animal parasiticides market in 2019

North America accounted for the largest share of the animal parasiticides market in 2019, followed by Europe and the Asia Pacific. High pet spending,increased awareness about animal health, and the growing companion animal population are the major factors responsible for the large share of North America in the animal parasiticides market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=258895412

Global Key Players:

The prominent players in this market are Boehringer Ingelheim (Germany),Elanco (US), Zoetis (US), Merck & Co. (US), and Virbac (France).

Ashland Global Holdings Inc. (US), DuPont (US), BASF SE (Germany) are the Leading Players in the Pharmaceutical Excipients Market

COVID-19 Impact on Global Pharmaceutical Excipients Market:

The COVID-19 pandemic had a significant impact on the pharma industry. Lockdowns imposed in the wake of the outbreak disrupted the supply of raw materials from manufacturing hubs such as India and China. This slowed drug development and manufacturing, with severe impacts on companies that relied heavily on outsourcing. The entire pharmaceutical ecosystem was disrupted initially. Moreover, regulatory authorities also had to reframe and construct new laws to ensure maximum patient safety after drug consumption.

The end of the lockdowns saw the pharma industry gaining momentum, especially given the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The increasing demand for these drugs drove revenue growth for some companies. The above mentioned factors  suggest that the Covid-19 impact on the pharmaceutical excipients market is negligible as it is the starting material in manufacturing of pharmaceutical drugs.

Expected Revenue Growth:

The pharmaceutical excipients market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8% during the forecast period. The overall growth of the pharmaceutical excipients market is largely driven by the growing pharmaceuticals market, advancements in functional excipients, and the growing generics market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956

Growth Boosting Factors:

The rapidly growing biopharmaceuticals sector will also influence market growth for pharmaceutical excipients. However, the increasing regulatory stringency regarding the approval of drugs and excipients along with the cost and time-intensive drug development process are expected to restrain the growth of this market during the forecast period.

Global Key Players:

The global pharmaceutical excipients consist of a large number of leading market players based in developed countries. The prominent players in this market are Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), and Croda International (UK).

Other players in this market are Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France).

DuPont held the leading position in the pharmaceutical excipients market in 2020. DuPont offers a comprehensive portfolio of excipients, including rheology modifiers, tablet coatings, controlled release, stabilizers, solubilizers, binding agents, and masking agents. DuPont significantly invests in R&D activities to add innovative technologies and products to its portfolio, which, in turn, helps the company strengthen its presence in the pharmaceutical excipients market.

For instance, in 2019, DuPont invested USD 955 million in R&D activities. With a strong portfolio of pharmaceutical excipients and a focus on developing innovative products, the company is likely to maintain its strong position in this market in the coming years. Moreover, the company has a strong global presence and distribution network, with subsidiaries in more than 160 countries. It is further expanding inorganically through acquisitions.

Roquette Feres held the second position in the global market. Roquette is a global manufacturer of pharmaceutical excipients. The company has strengthened its position in this market through market expansion activities and innovations. The company owns more than 5,000 patents and has around 300 employees dedicated to the R&D of novel solutions. Roquette is currently focusing on expanding its presence in emerging economies. In line with this, Roquette acquired Itacel, the excipient division of Blanver in Brazil.

Roquette also acquired a majority stake in the Lithuaniabased company, Amilina, a producer of starch and derivatives. While achieving expansion in high-growth international markets, the company also intends to expand its pharmaceutical excipients product portfolio with the launch of new specialty excipients for the pharmaceutical industry. In this regard, Roquette introduced Maize Starch IP/BP and Mannitol IP, which are used as fillers in the pharmaceutical industry. The company also launched three new excipient brands. For its future growth, Roquette intends to further strengthen its existing relationships with key customers by organizing customer meetings, field visits, and training sessions on proactive quality management regularly in order to understand company functionalities and product portfolios better.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=956

Asia Pacific is expected to account for the highest CAGR for players operating in the Pharmaceutical Excipients market

The Asia Pacific is the fastest-growing and most dynamic pharmerging market globally, poised to be the most attractive regional market due to its large base of generic drug manufacturers. Several factors, such as the growing Asian scientific base (due to the establishment of R&D centers and manufacturing facilities by major players in recent years); growth in the Asian pharmaceutical markets and pharmaceutica manufacturing capabilities; and the large patient pool are contributing to the growth of the pharmaceutical excipients market in the APAC.

Neurovascular Devices Market - Global Key Players & Different Growth Strategies Adopted by Them

The key players in the neurovascular devices market focused on various strategies such as product launches & enhancements; agreements and collaborations; strategic acquisitions; and expansions to increase market shares in the global market. Product launches & enhancements were the key strategies adopted by major industry players to achieve the desired market growth during 2013-2016.

This strategy was mainly adopted by Stryker Corporation (U.S.), Medtronic plc (U.S.), Johnson & Johnson (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Abbott Laboratories (U.S.), Merit Medical Systems, Inc. (U.S.), W. L. Gore & Associates, Inc. (U.S.), and MicroPort Scientific Corporation (China). Apart from product launches & enhancements, many prominent players also adopted agreements & collaborations as the key growth strategy to strengthen market presence, enhance R&D capabilities, and to expand distribution networks to generate additional demand by sensitizing end users through an increase in availability of neurovascular products

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847

Stryker Corporation (U.S.) held the leading position in the global neurovascular devices market, in 2015. The company has a wide range of neurovascular products, including guidewires (such as Transend guidewires and Synchro guidewires), microcatheters (such as Excelsior SL-10 microcatheter and Excelsior 1018 microcatheter), balloon occlusion catheter (Transform occlusion balloon catheter), and detachable coils (such as Target XL detachable coils, Target Nano Detachable Coils, Target 360 Detachable Coils, and Target 3D Detachable Coils). The company has a strong presence in North America, Europe, the Middle East, Africa, Asia-Pacific and other countries.

The company has more than 30 manufacturing facilities in countries such as the U.S., China, Turkey, Germany, Ireland, Switzerland, and France. It primarily focuses on inorganic business growth strategies such as product development & commercialization, acquisitions, and market expansions. The company launched and commercialized clot retrieval device, namely, Trevo ProVue in November 2012 and acquired Synergetics USA, Inc. in April 2016, Trauson Holdings Company Limited (China) in March 2013, and Surpass Medical, Ltd. (Israel) in November 2012 to strengthen its R&D capabilities and expand its product portfolio in the global market.

Medtronic plc (Ireland) held the second position in the global neurovascular devices market, in 2015. The company has a strong foothold in the market with a broad range of neurovascular products which include embolic coils, liquid embolics, microcatheters, guidewires, balloon catheters, clot retrieval devices, flow diversion devices, vascular embolization devices, remodeling devices, flow restoration devices, cranial repair products (such as TiMesh system and INVISx Cranial Fixation System), and shunts (such as StrataMR Adjustable Pressure Valve, Strata Adjustable Pressure Valve with Siphon Control and Strata NSC Adjustable Pressure Valve with No Siphon Control).

To strengthen its current position and to gain a larger share in the market, the company aggressively focuses on inorganic growth strategies such as product development & commercialization, acquisitions, and market expansions. During 2012–2016, the company developed and commercialized several neurovascular products such as Solitaire (TM) stent retriever device (November 2016), Pivox Oblique lateral spinal system with lateral plate for OLIF25 (July 2016), infuse bone graft (December 2015), and StealthStation electromagnetic (EM) surgical navigation system instruments (May 2015). In addition, the acquisition of Medina Medical (U.S.), Covidien plc (U.S.), Reverse Medical Corporation (U.S.), and Nfocus Neuromedical, Inc. (U.S.) enhanced its R&D capabilities and expanded its product portfolio in the global market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=847

Geographical Growth:

On the basis of geography, neurovascular devices market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is the fastest-growing geographic segment in the neurovascular devices/interventional neurology market. The large market growth of this geographic segment can be attributed to the presence of a large patient population base for target diseases, rising awareness among neurosurgeons related to the benefits offered by interventional neurology devices, and ongoing government initiatives to modernize & expand healthcare infrastructure.

Key Growth Strategy Adopted by Players Operating in the Global Process Analytical Technology Market

Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Danaher Corporation (U.S.) are the leading players in the global process analytical technology market. The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), Shimadzu Corporation (Japan), ABB Ltd. (U.S.), Carl Zeiss AG (Germany), Emerson Electric Co. (U.S.), and Mettler-Toledo International Inc. (U.S.).

Thermo Fisher Scientific Inc. dominated the global PAT market in 2016. The company offers analytical technologies through its analytical instruments business segments, which cater to the markets in developed as well as developing countries. The company mainly focuses on product launches as its key growth strategy. The company launched many products between January 2016 and July 2016, including the Vanquish Flex Binary UHPLC system, Q Exactive BioPharma, Exactive GC Orbitrap GC-MS, Dionex Chromeleon 7.2 Chromatography Data System, and MAbPac RP column.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=59564006

The company also enters into collaborations, agreements, and partnerships as well as adopts expansions as a growth strategy to maintain its market presence. Thermo Fisher has a significant global footprint in almost all the regions of the world owing to its strong sales and distribution network.

Agilent Technologies, Inc. held the second position in the global PAT market in 2016. Agilent Technologies operates under three business segments, namely, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company focuses on organic growth strategies such as product launches and expansions in various territories to keep up with its competitors. Agilent offers a broad portfolio of PAT solutions and has a vast geographic presence with distribution channels across the Americas, Europe, Asia-Pacific, and the Middle East.

Danaher Corporation held the third position in the global PAT market. The company offers its process analytical technology solutions through its subsidiary, AB Sciex LLC, (U.S.). It focuses on strategies such as partnerships and collaborations to enhance its technical strengths as well as secure its market position. The company also focuses on product launches to improve its portfolio. The company has a global presence in developed regions such as North America and Europe as well as developing regions such as Asia-Pacific and Latin America.

Companies in the process analytical technology market are majorly focusing on product launches for strengthening their market share; this strategy accounted for 63.5% of the total number of strategic developments undertaken by key players in this market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=59564006 

Respiratory Care Devices Market worth $29.9 billion by 2025

COVID-19 Impact on the Global Respiratory Care Devices Market:

The COVID-19 outbreak in Wuhan, China, led to the rapid establishment of several hospitals for treating the increasing number of patients. This has been mirrored in other countries as well—Italy and the US also built large hospitals within days to accommodate a growing patient population. In New York, US, the army converted the Javits convention center into a 2,900-bed hospital within four days. Critical care devices are being manufactured in increased quantities to meet growing demand. The state of affairs resulting from the pandemic has resulted in alliances between healthcare and non-healthcare industries to manufacture respiratory care devices.

Respiratory Care Devices Market Dynamics

Drivers: Outbreak of infectious diseases affecting the respiratory system

Infectious respiratory diseases directly drive demand for respiratory care. COVID-19 is the most recent and significant of these diseases; the pandemic has resulted in a surge in demand for personal protection equipment and ventilators, among others. The demand for ventilators has also grown due to the COVID-19 outbreak, resulting in governmental and industrial support for driving the pace of manufacturing. This is indicative of the emphasis on respiratory care in the background of an outbreak; the market is expected to show a healthy growth rate, as a result.

Download PDF Brochure
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368

Restrains: Unfavorable reimbursement scenario

Many patients rely on reimbursements to receive treatment. The diagnostic industry as a whole and respiratory care diagnostics, in particular, is presently facing the challenge of lack of reimbursements for various diagnostic tests. Reimbursement policies are dispersed in Europe and are available only for PAP devices and oral appliances in select countries (devices that are not covered by insurance have a low market share in the region). Also, the majority of countries in the Asian and RoW regions have negligible reimbursement coverage for respiratory care devices.

The hospitals segment accounted for the largest market share in 2019

Based on the end-user, the respiratory care devices market is segmented into hospitals, home care settings, and ambulatory care centers. In 2019, hospitals accounted for the largest market share. Their financial capabilities, which allow them to purchase expensive instruments, and the availability of trained professionals to operate these instruments, have ensured the high percentage of hospitals in this market. Home care settings are expected to witness the highest growth during the forecast period, mainly due to the development of compact and lightweight respiratory care devices that are easier to carry and operate.

Asia Pacific market to witness the highest growth during the forecast period

The respiratory market is divided into five regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. These regions are further analyzed at the country levels. North America held the largest share of the respiratory care devices market in 2019, followed by Europe and the Asia Pacific. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, due to due to the presence of a large pool of respiratory patients, increasing healthcare expenditure, rapidly developing healthcare infrastructure, rising per capita income, growing middle-class population, and growing prevalence of tobacco smoking in this region.

Global Key Players:

Some of the prominent players operating in this market include Philips Healthcare (Netherlands), ResMed (US), Medtronic (Ireland), Masimo Corporation (US), Fisher & Paykel Healthcare (New Zealand), Drager AG (Germany), Invacare Corporation (US), Nihon Kohden (Japan), Getinge AB (Sweden) and Air Liquide (France).

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=368

Expected Revenue Growth:

The respiratory care devices market is expected to reach USD 29.9 billion by 2025 from USD 16.0 billion in 2019, at a CAGR of -12.5% during the forecast period of 2020 to 2025. Due to the outbreak of corona virus globally, there is a sudden rise in the demand for respiratory care devices. Thus, the respiratory care devices market witnessed a CAGR of 261.1% between 2019 and 2020. In 2020, respiratory care devices market reached to USD 58.1 billion.

The growth of this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidence of preterm births, and lifestyle changes. However, a lack of awareness—leading to a large underdiagnosed and undertreated population—and the harmful effects of certain respiratory care devices on neonates have hampered market growth to an extent.